NASDAQ:CALX 2 February 2026

Calix (CALX) stock jumps as buyback talk returns and traders eye Feb. 24 investor day

Calix shares rose 6.5% to $47.59 Monday after the company projected sequential revenue growth but warned of near-term margin pressure from its cloud platform migration. CEO Michael Weening reported Q4 revenue of $272.4 million and record non-GAAP gross margin of 58%. Investors await further guidance at Calix’s Feb. 24 investor day.

2 February 2026

NASDAQ:CALX·Share Buybacks·Stock Market

Celldex Therapeutics Shares Trade Below Fair Value Despite Strong 1-Year Returns
March 19, 2026, 2:33 AM EDT. Celldex Therapeutics (Nasdaq: CLDX) shares fell to $28.54, down recently after a strong 24.09% gain over the past month and a 43.06% total return over the past year. Despite minimal revenue of $1.55 million against a $1.97 billion market cap, Simply Wall St's discounted cash flow (DCF) model estimates fair value at $96.92, suggesting the stock is significantly undervalued. The model bases valuation on future cash flow expectations from drug candidates like barzolvolimab and CDX-622, not current earnings. However, net losses of $258.76 million raise concerns over funding risks. The price-to-book ratio of 3.6x is below peers at 13.4x but above the broader biotech sector at 2.6x. Investors should weigh optimistic pipeline potential against clinical trial and financial challenges.